Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Justice Department Investigating Novation; BD Faces Whistleblower Lawsuit

This article was originally published in The Gray Sheet

Executive Summary

BD maintains it is not the target of a U.S. Department of Justice criminal investigation of Novation, despite being subpoenaed to provide evidence in the case against the group purchasing organization

You may also be interested in...



Medtronic whistleblowers

Firm receives copy of second civil qui tam complaint Sept. 2 on "allegations under the False Claims Act" similar to charges a September 2003 whistleblower brought against its Sofamor Danek spinal division, according to Medtronic's recent 110-Q filing. The Department of Justice is investigating "certain payments and other services provided to physicians by Medtronic" that may have been "improper inducements under the federal anti-kickback statute." The case is under seal at Memphis federal court. In its quarterly report filed with SEC Aug. 13, BD revealed it has been cited by a qui tam complaint, also on the False Claims Act (2"The Gray Sheet" Aug. 30, 2004, p. 22)...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel